Acute promyelocytic Leukemia: Where did we start, where are we now, and the future

Blood Cancer Journal

Volumn 5, Issue 4, 2015, Pages

  Coombs, C C ^a   Tavakkoli, M ^a   Tallman, M S ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ARSENIC TRIOXIDE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; BLEEDING TENDENCY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CONSOLIDATION CHEMOTHERAPY; DRUG TREATMENT FAILURE; HUMAN; INCIDENCE; LEUKEMIA REMISSION; LOW RISK PATIENT; MAINTENANCE CHEMOTHERAPY; META ANALYSIS (TOPIC); PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); ADVERSE DRUG REACTION; LEUKEMIA, PROMYELOCYTIC, ACUTE; PATHOLOGY; TREATMENT FAILURE;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES; TREATMENT FAILURE; TRETINOIN;

EID: 84961509269     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.25     Document Type: Review

References (106)

1. Hillestad LK Acute promyelocytic leukemia. Acta Med Scand 1957; 159: 189-194.
2. Pisciotta AV, Schulz EJ. Fibrinolytic purpura in acute leukemia. Am J Med 1955; 19: 824-828.
3. Cooperberg AA, Neiman GM. Fibrinogenopenia and fibrinolysis in acute myelogenous leukemia. Ann Intern Med 1955; 42: 706-711.
4. Fisher S, Ramot B, Kreisler B. Fibrinolysis in Acute Leukemia. Israel Med J 1960; XIX: 195-198.
5. Ghitis J. Acute promyelocytic leukemia? Blood 1963; 21: 237-240.
6. Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD. Evidence for a 15; 17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984; 76: 827-841.
7. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113: 1875-1891.
8. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1253.
9. Bernard J, Weil M, Boiron M, Jacquillat C, Flandrin G, Gemon MF. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood 1973; 41: 489-496.
10. Bernard PJ, Mathe G, Boulay J, Ceoard B, Chome J. La leucose aigue a promyelocytes. Schweiz Med Wochenschr 1959; 23: 604-608.
11. Baker WG, Bang NU, Nachman RL, Raafat F, Horowitz HI. Hypofibrinogenemic hemorrhage in acute myelogenous leukemia treated with heparin. With autopsy findings of widespread intravascular clotting. Ann Intern Med 1964; 61: 116-123.
12. Rosenthal RL Acute promyelocytic leukemia associated with hypofibrinogenemia. Blood 1963; 21: 495-508.
13. Didisheim P, Trombold JS, Vandervoort LE, Mibashan RS. Acute promyelocytic leukemia with fibrinogen and factor V deficiencies. Blood 1964; 23: 717-728.
14. Drapkin RL, Gee TS, Dowling MD, Arlin Z, McKenzie S, Kempin S et al. Prophylactic heparin therapy in acute promyelocytic leukemia. Cancer 1978; 41: 2484-2490.
15. Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, Clarkson BD. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood 1989; 73: 1116-1122.
16. Sanz MA, Jarque I, Martin G, Lorenzo I, Martinez J, Rafecas J et al. Acute promyelocytic leukemia. Therapy results and prognostic factors. Cancer 1988; 61: 7-13.
17. Cordonnier C, Vernant JP, Brun B, Heilmann MG, Kuentz M, Bierling P et al. Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 1985; 55: 18-25.
18. Petti MC, Avvisati G, Amadori S, Baccarani M, Guarini AR, Papa G et al. Acute promyelocytic leukemia: clinical aspects and results of treatment in 62 patients. Haematologica 1987; 72: 151-155.
19. Arlin Z, Kempin S, Mertelsmann R, Gee T, Higgins C, Jhanwar S et al. Primary therapy of acute promyelocytic leukemia: results of amsacrine- and daunorubicin-based therapy. Blood 1984; 63: 211-212.
20. Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75: 2112-2117.
21. Kantarjian HM, Keating MJ, Walters RS, Estey EH, McCredie KB, Smith TL et al. Acute promyelocytic leukemia. Am J Med 1986; 80: 789-797.
22. Head D, Kopecky KJ, Weick J, Files JC, Ryan D, Foucar K et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 1995; 86: 1717-1728.
23. Goldberg MA, Ginsburg D, Mayer RJ, Stone RM, Maguire M, Rosenthal DS et al. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood 1987; 69: 187-191.
24. Collins AJ, Bloomfield CD, Peterson BA, McKenna RW, Edson JR. Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicinprednisone remission induction. Arch Intern Med 1978; 138: 1677-1680.
25. Leone G, Mango G, Alfano G. Disseminated intravascular coagulation in acute promyelocytic leukemia. Possibility of treatment with glucocorticoids at high doses. Nouv Rev Fr Hematol 1978; 20: 395-401.
26. Daly PA, Schiffer CA, Wiernik PH. Acute promyelocytic leukemia-clinical management of 15 patients. Am J Hematol 1980; 8: 347-359.
27. Avvisati G, Petti MC, Petrucci MT, Falconi E, Tirindelli MC, Mandelli F. Treatment of recurrent promyelocytic leukemia with a combination regimen utilizing amsacrine, cytosine arabinoside and 6-thioguanine (AAT). Haematologica 1989; 74: 279-282.
28. Marty M, Ganem G, Fischer J, Flandrin G, Berger R, Schaison G et al. [Acute promyelocytic leukemia: retrospective study of 119 patients treated with daunorubicin]. Nouv Rev Fr Hematol 1984; 26: 371-378.
29. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111: 2505-2515.
30. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021-1028.
31. Chen ZX, Xue YQ, Zhang R, Tao RF, Xia XM, Li C et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413-1419.
32. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76: 1704-1709.
33. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572.
34. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94: 1192-1200.
35. Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Loffler H et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 2000; 14: 1362-1370.
36. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo ItalianoMalattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90: 1014-1021.
37. Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998; 16: 78-85.
38. Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/ RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999; 94: 3015-3021.
39. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993; 82: 3241-3249.
40. de Botton S, Chevret S, Coiteux V, Dombret H, Sanz M, San Miguel J et al. Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. Leukemia 2003; 17: 339-342.
41. Ades L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006; 24: 5703-5710.
42. Burnett AK, Hills RK, Grimwade D, Goldstone AH, Hunter A, Milligan D et al. Idarubicin and ATRA is as effective as MRC chemotherapy in patients with acute promyelocytic leukaemia with lower toxicity and resource usage: preliminary results of the MRC AML15 Trial. ASH Annual Meeting Abstracts. 2007; 110: 589.
43. Ades L, Raffoux E, Chevret S, de Botton S, Guerci A, Pigneux A et al. Is AraC required in the treatment of standard risk APL? Long term results of a randomized trial (APL 2000) from the French Belgian Swiss APL Group. ASH Annual Meeting Abstracts 2010; 116: 13.
44. Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M et al. AIDA (all-trans retinoic acid+idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996; 88: 1390-1398.
45. Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103: 1237-1243.
46. Sanz MA, Montesinos P, Rayon C, Holowiecka A, de la Serna J, Milone G et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010; 115: 5137-5146.
47. Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 2012; 120: 1570-1580, quiz 752.
48. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315-3324.
49. Zheng PZ, Wang KK, Zhang QY, Huang QH, Du YZ, Zhang QH et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci USA 2005; 102: 7653-7658.
50. Gianni M, Koken MH, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998; 91: 4300-4310.
51. Dos Santos GA, Kats L, Pandolfi PP. Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med 2013; 210: 2793-2802.
52. Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, Berthier C et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 2008; 14: 1333-1342.
53. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 5328-5335.
54. Iland HJ, Collins M, Hertzberg MS, Seldon M, Grigg AP, Firkin F et al. Final analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 Trial: all-trans retinoic acid (ATRA), intravenous arsenic trioxide (ATO) and idarubicin (IDA) as initial therapy for acute promyelocytic leukemia (APL). American Society of Hematology Meeting, San Francisco, CA, USA, 2014.
55. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006; 107: 3469-3473.
56. Ravandi F, Estey EH, Cortes JE, O'Brien S, Pierce SA, Brandt M et al. Phase II study of all-trans retinoic acid (ATRA), arsenic trioxide (ATO), with or without gemtuzumab ozogamicin (GO) for the frontline therapy of patients with acute promyelocytic leukemia (APL)Blood (ASH Annual Meeting Abstracts) 2010; 116: Abstract 1080.
57. Pellicori P, Calicchia A, Lococo F, Cimino G, Torromeo C. Subclinical anthracycline cardiotoxicity in patients with acute promyelocytic leukemia in long-term remission after the AIDA protocol. Congest Heart Fail (Greenwich, Conn) 2012; 18: 217-221.
58. Andersen MK, Pedersen-Bjergaard J. Therapy-related MDS and AML in acute promyelocytic leukemia. Blood 2002; 100: 1928-1929, author reply 9.
59. Garcia-Manero G, Kantarjian HM, Kornblau S, Estey E. Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL). Leukemia 2002; 16: 1888.
60. Latagliata R, Petti MC, Fenu S, Mancini M, Spiriti MA, Breccia M et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 2002; 99: 822-824.
61. Montesinos P, Gonzalez JD, Gonzalez J, Rayon C, de Lisa E, Amigo ML et al. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy. J Clin Oncol 2010; 28: 3872-3879.
62. Platzbecker U, Avvisati G, Ehninger G, Cicconi L, Thiede C, Ferrara F et al. Improved outcome with ATRA-arsenic trioxide compared to ATRAchemotherapy in non-high risk acute promyelocytic leukemia - updated results of the Italian-German APL0406 Trial on the Extended Final Series. American Society of Hematology Meeting, San Francisco, CA, USA, 2014.
63. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013; 369: 111-121.
64. Efficace F, Mandelli F, Avvisati G, Cottone F, Ferrara F, Di Bona E et al. Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: healthrelated quality-of-life outcomes. J Clin Oncol 2014; 32: 3406-3412.
65. Eghtedar A, Rodriguez I, Kantarjian H, O'Brien S, Daver N, Garcia-Manero G et al. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. Leuk Lymph 2014; e-pub ahead of print 3 November 2014; doi:10.3109/10428194.2014.953143.
66. Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010; 116: 3171-3179.
67. Flanagan SA, Meckling KA. Alltrans-retinoic acid increases cytotoxicity of 1-beta-D-arabinofuranosylcytosine in NB4 cells. Cancer Chemother Pharmacol 2003; 51: 363-375.
68. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010; 116: 3751-3757.
69. Gore SD, Gojo I, Sekeres MA, Morris L, Devetten M, Jamieson K et al. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 2010; 28: 1047-1053.
70. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009; 27: 504-510.
71. Muchtar E, Vidal L, Ram R, Gafter-Gvili A, Shpilberg O, Raanani P. The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission. Cochrane Database Syst Rev 2013; 3: Cd009594.
72. Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E et al. Arsenic trioxide during consolidation for patients with previously untreated low/ intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol 2014; 165: 497-503.
73. Breccia M, Minotti C, Latagliata R, Loglisci G, Salaroli A, Loglisci MG et al. Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols. Leuk Res 2013; 37: 383-385.
74. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1995; 85: 1083-1094.
75. Zhu HH, Qin YZ, Huang XJ. Resistance to arsenic therapy in acute promyelocytic leukemia. N Engl J Med 2014; 370: 1864-1866.
76. Tallman MS Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol 2007; 20: 57-65.
77. Specchia G, Lo Coco F, Vignetti M, Avvisati G, Fazi P, Albano F et al. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. J Clin Oncol 2001; 19: 4023-4028.
78. Lou Y, Suo S, Tong Y, Tong H, Qian W, Meng H et al. Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy. Ann Hematol 2014; 93: 941-948.
79. Pemmaraju N, Tanaka MF, Ravandi F, Lin H, Baladandayuthapani V, Rondon G et al. Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk 2013; 13: 485-492.
80. Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K et al. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood 2013; 121: 3095-3102.
81. Holter Chakrabarty JL, Rubinger M, Le-Rademacher J, Wang HL, Grigg A, Selby GB et al. Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission. Biol Blood Marrow Transplant 2014; 20: 1021-1025.
82. Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL et al. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. Bone Marrow Transplant 2014; 50: 40-44.
83. Micol JB, Raffoux E, Boissel N, Lengline E, Canet E, Daniel MT et al. Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials. Eur J Cancer 2014; 50: 1159-1168.
84. Lengfelder E, Hofmann WK, Nolte F. Management of elderly patients with acute promyelocytic leukemia: progress and problems. Ann Hematol 2013; 92: 1181-1188.
85. Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011; 118: 1248-1254.
86. Iland HJ, Seymour JF, Wei A. Optimal approach for high-risk acute promyelocytic leukemia. Curr Opin Hematol 2014; 21: 102-113.
87. Altman JK, Rademaker A, Cull E, Weitner BB, Ofran Y, Rosenblat TL et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res 2013; 37: 1004-1009.
88. Rashidi A, Riley M, Goldin TA, Sayedian F, Bayerl MG, Aguilera NS et al. Delay in the administration of all-trans retinoic acid and its effects on early mortality in acute promyelocytic leukemia: final results of a multicentric study in the United States. Leuk Res 2014; 38: 1036-1040.
89. Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood 2009; 114: 5126-5135.
90. Grisariu S, Spectre G, Kalish Y, Gatt ME. Increased risk of central venous catheterassociated thrombosis in acute promyelocytic leukemia: a single-institution experience. Eur J Haematol 2013; 90: 397-403.
91. Kumana CR, Au WY, Lee NS, Kou M, Mak RW, Lam CW et al. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol 2002; 58: 521-526.
92. Au WY, Kumana CR, Kou M, Mak R, Chan GC, Lam CW et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood 2003; 102: 407-408.
93. Siu CW, Au WY, Yung C, Kumana CR, Lau CP, Kwong YL et al. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood 2006; 108: 103-106.
94. Au WY, Kumana CR, Lee HK, Lin SY, Liu H, Yeung DY et al. Oral arsenic trioxidebased maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood 2011; 118: 6535-6543.
95. Zhu HH, Wu DP, Jin J, Li JY, Ma J, Wang JX et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol 2013; 31: 4215-4221.
96. Zeidan AM, Gore SD. New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach. Clin Cancer Res 2014; 20: 4985-4993.
97. Takeshita A, Shinjo K, Naito K, Matsui H, Sahara N, Shigeno K et al. Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells. Leukemia 2005; 19: 1306-1311.
98. Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012; 379: 1508-1516.
99. Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA et al. Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol 2012; 30: 3921-3923.
100. Stein EM, Stein A, Walter RB, Fathi AT, Lancet JE, Kovacsovics TJ et al. Interim analysis of a phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia (AML). American Society of Hematology Meeting, San Francisco, CA, USA, 2014.
101. Lo-Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004; 104: 1995-1999.
102. Hashimoto Y, Kagechika H, Kawachi E, Fukasawa H, Saito G, Shudo K. Correlation of differentiation-inducing activity of retinoids on human leukemia cell lines HL-60 and NB4. J Cancer Res Clin Oncol 1995; 121: 696-698.
103. Tobita T, Takeshita A, Kitamura K, Ohnishi K, Yanagi M, Hiraoka A et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 1997; 90: 967-973.
104. Shinagawa K, Yanada M, Sakura T, Ueda Y, Sawa M, Miyatake J et al. Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial. J Clin Oncol 2014; 32: 3729-3735.
105. Sanford D, LoCoco F, Sanz MA, Di Bona E, Coutre S, Altman JK et al. Single agent tamibarotene has activity in acute promyelocytic leukemia patients previously treated with ATRA and arsenic trioxide, but does not produce durable responses. American Society of Hematology Meeting, San Francisco, CA, USA, 2014.
106. Shetty AV, Ravandi F, Alapati N, Borthakur G, Garcia-Manero G, Kadia TM et al. Survivorship in APL-outcomes of acute promyelocytic leukemia (APL) patients (pts) after maintaining complete remission (CR) for at least 3 years. American Society of Hematology Meeting, San Francisco, CA, USA, 2014.